JNJ-80948543

DRUG3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin

Phase 1

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Active, not recruitingNCT05424822

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin

Start: 2022-08-18End: 2027-07-30Updated: 2026-03-13

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Active, not recruitingNCT06139406

Janssen Research & Development, LLCLymphoma, Non-Hodgkin

Start: 2023-12-06End: 2026-08-31Updated: 2026-03-13

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

Active, not recruitingNCT06660563

Janssen Research & Development, LLCLymphoma, Non-Hodgkin

Start: 2024-10-22End: 2026-09-21Updated: 2026-03-13

Related Papers

Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.

2026-02-26

JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Blood2024-11-053 citations